Potential biomarkers associated with malignancy in uterine mesenchymal tumors

[1] Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemi-ology, and end results analysis of 2677 cases of uterine sarcoma 1989–1999. Gynecologic Oncology. 2004; 93: 204–208.

[2] Ricci S, Stone RL, Fader AN. Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation. Gynecologic Oncology. 2017; 145: 208–216.

[3] Sagae S, Yamashita K, Ishioka S, Nishioka Y, Terasawa K, Mori M, et al. Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan. Oncology. 2004; 67: 33–39.

[4] Akahira J, Tokunaga H, Toyoshima M, Takano T, Nagase S, Yoshinaga K, et al. Prognoses and prognostic factors of carcinosarcoma, endometrial stromal sarcoma and uterine leiomyosarcoma: a comparison with uterine endometrial adenocarcinoma. Oncology. 2006; 71: 333–340.

[5] Wada H, Enomoto T, Fujita M, Yoshino K, Nakashima R, Kurachi H, et al. Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Research. 1997; 57: 5379–5385.

[6] Bell SW, Kempson RL, Hendrickson MR. Problematic Uterine Smooth Muscle Neoplasms. American Journal of Surgical Pathology. 1994; 18: 535–558.

[7] Hayashi T. Current status of chemotherapy for uterine sarcoma in Japan. JAMA Oncology. 2021; 7: 1–2.

[8] Hendrickson MR, Tavassoli FA, Kempson RL, McCluggage WG, Haller U, Kubik-Huch RA.  Mesenchymal tumours and related lesions. In Tavassoli FA, Devilee P (eds.) World Health Organization Classification of Tumours. Pathology & Genetics.  Tumours of the Breast and Female Genital Organs (pp. 233–244).  Lyon: IARC Press. 2003.

[9] Leath CA, Huh WK, Hyde J, Cohn DE, Resnick KE, Taylor NP, et al. A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecologic Oncology. 2007; 105: 630–634.

[10] Riopel J, Plante M, Renaud M, Roy M, Têtu B. Lymph node metastases in low-grade endometrial stromal sarcoma. Gynecologic Oncology. 2005; 96: 402–406.

[11] Zang Y, Dong M, Zhang K, Gao C, Guo F, Wang Y, et al. Hormonal therapy in uterine sarcomas. Cancer Medicine. 2019; 8: 1339–1349.

[12] Hayashi T, Kodama S, Faustman DL. LMP2 expression and proteasome activity in NOD mice. Nature Medicine. 2000; 6: 1065–1066.

[13] Hayashi T, Faustman DL. Development of spontaneous uterine tumors in low molecular mass polypeptide-2 knockout mice. Cancer Research. 2002; 62: 24–27.

[14] Hayashi T, Horiuchi A, Sano K, Hiraoka N, Kasai M, Ichimura T, et al. Potential role of LMP2 as tumor-suppressor defines new targets for uterine leiomyosarcoma therapy. Scientific Reports. 2011; 1: 180.

[15] Hayashi T, Horiuchi A, Aburatani H, Ishiko O, Yaegashi N, Kanai Y, et al. Potential biomarker for human uterine leiomyosarcoma. Journal of Clinical Medicine Research. 2014; 6: 392–394.

[16] Hayashi T, Kawano M, Sano K, Ichimura T, Gur G, Yaish P, et al. A novel diagnostic biomarker for human uterine leiomyosarcoma: PSMB9/β1i. Chinese Clinical Oncology. 2017; 6: 22.

[17] Hayashi T, Horiuch A, Aburatani H, Yaegashi N, Tonegawa S, Konishi I. A potential diagnostic biomarker: Proteasome LMP2/b1i-differential expression in human uterus neoplasm. 2012. Available at: https://www.nature.com/articles/npre.2012. 7082.1 (Accessed: 2 April 2012).

[18] Watanabe K, Hayashi T, Katsumata M, Sano K, Abiko K, Konishi I. Development of Uterine Leiomyosarcoma during Follow-up after Caesarean Section in a Woman with Uterine Leiomyoma. Anticancer Research. 2021; 41: 3001–3010.

[19] Donnellan R, Chetty R. Cyclin E in human cancers. FASEB Journal. 1999; 13: 773–780.

[20] Geng Y, Yu Q, Sicinska E, Das M, Schneider JE, Bhattacharya S, et al. Cyclin E ablation in the mouse. Cell. 2003; 114: 431–443.

[21] Méndez J. Cell proliferation without cyclin E-CDK2. Cell. 2003; 114: 398–399.

[22] Hayashi T, Kawano M, Ichimura T, Ida K, Ando H, Zharhary D, et al. Molecular Pathology and Novel Clinical Therapy for Uterine Leiomyosarcoma. Anticancer Research. 2016; 36: 4997–5007.

[23] Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, et al. Cyclin E and survival in patients with breast cancer. New England Journal of Medicine. 2002; 347: 1566–1575.

[24] Matsuda M, Ichimura T, Kasai M, Murakami M, Kawamura N, Hayashi T, et al. Preoperative diagnosis of usual leiomyoma, atypical leiomyoma, and leiomyosarcoma. Sarcoma. 2014; 2014: 498682.

[25] Hayashi T, Sano K, Ichimura T, Kanai Y, Zharhary D, Aburatani H, et al. Characteristics of Leiomyosarcoma: Induction ofHematogenous Metastasis by Isolated Uterine Mesenchymal Tumor Stem-like Cells. Anticancer Research. 2020; 40: 1255–1265.

[26] Hayashi T, Kobayashi Y, Sano K, Horiuchi A, Konishi I. Patent: Detection of uterine leiomyosarcoma using LMP2. Application JP2007548042A events. 2019. Available at: https://upload.u min.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000044182 (Accessed: 4 December 2019).

[27] Hayashi T, Ichimura T, Yaegashi N, Shiozawa T, Konishi I. Expression of CAVEOLIN 1 in uterine mesenchymal tumors: no relationship between malignancy and CAVEOLIN 1 expression. Biochemical and Biophysical Research Communications. 2015; 463: 982–987.

[28] Hayashi T, Sano K, Ichimura T, Tonegawa S, Yaegashi N, Konishi I. Diagnostic biomarker candidates including NT5DC2 for humanuterine mesenchymal tumors. International Journal of Trend in Scientific Research and Development. 2021; 5: 604–606.

[29] Ravegnini G, Mariño-Enriquez A, Slater J, Eilers G, Wang Y, Zhu M, et al. MED12 mutations in leiomyosarcoma and extrauterine leiomyoma. Modern Pathology. 2013; 26: 743–749.

[30] Smooth muscle tumor of uncertain malignant potential of the uterine corpus. Female Genital Tumours WHO Classification of Tumours (pp. 279–280). 5th edn. WHO Classification of Tumours Editorial Board. World Health Organization. 2020.

[31] Hayashi T, Ichimura T, Kasai M, Sano K, Zharhary D, Shiozawa T, et al. Characterization of Leiomyomatoid Angiomatous Neuroendocrine Tumour (LANT)-like Tumour in the Myometrium with Histopathological Examination. Anticancer Research. 2017; 37: 1765–1772.